GlassScriptPhysician profile
Amber Bokhari
NPI 1255807228
$7,492.12
in general payments reported to CMS, 2019-2025
26 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,978 · 2022: $1,272 · 2023: $1,295 · 2024: $730 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,241.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,472.88 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,269.47 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $627.02 | 2021-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $516.29 | 2021-2023 | Uzedy, Austedo |
| Lundbeck LLC | $496.55 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $424.10 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $317.50 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $269.11 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $265.56 | 2022-2025 | Auvelity |
| Neos Therapeutics, LP | $223.25 | 2021-2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $217.04 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $193.94 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $178.32 | 2021-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $173.43 | 2021-2024 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $156.43 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $149.16 | 2021 | |
| Neurocrine Biosciences, INC. | $115.76 | 2021-2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $110.00 | 2022 | |
| Noven Therapeutics, LLC | $76.02 | 2021 | |
| Adlon Therapeutics L.P. | $73.00 | 2021 | |
| Avanir Pharmaceuticals, INC. | $47.01 | 2021 | |
| Almatica Pharma LLC | $37.55 | 2022 | |
| Merck Sharp & Dohme LLC | $27.55 | 2021 | |
| Ironshore Pharmaceuticals INC. | $24.17 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.03 | 2022 | |
| Corium, LLC | $12.98 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Bokhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.